Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BioCryst Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding BioCryst Pharmaceuticals, Inc.’s stock price such as:

• BioCryst Pharmaceuticals, Inc.’s current stock price and volume
• Why BioCryst Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for BCRX from analysts
• BCRX’s stock price momentum as measured by its relative strength

About BioCryst Pharmaceuticals, Inc. (BCRX)

Before we jump into BioCryst Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Want to learn more about BioCryst Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BioCryst Pharmaceuticals, Inc..

BioCryst Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, BioCryst Pharmaceuticals, Inc.’s stock price was $8.980.

BioCryst Pharmaceuticals, Inc. is down 2.81% from its previous closing price of $9.240.

During the last market session, BioCryst Pharmaceuticals, Inc.’s stock traded between $8.925 and $9.250. Currently, there are approximately 242.26 million shares outstanding for BioCryst Pharmaceuticals, Inc..

BioCryst Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

BioCryst Pharmaceuticals, Inc. Stock Price History

BioCryst Pharmaceuticals, Inc.’s (BCRX) price is currently down 10.2% so far this month.

During the month of July, BioCryst Pharmaceuticals, Inc.’s stock price has reached a high of $11.220 and a low of $8.925.

Over the last year, BioCryst Pharmaceuticals, Inc. has hit prices as high as $11.220 and as low as $6.000. Year to date, BioCryst Pharmaceuticals, Inc.’s stock is up 15.13%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BioCryst Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded BioCryst Pharmaceuticals, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate BioCryst Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BioCryst Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

BioCryst Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BioCryst Pharmaceuticals, Inc. (BCRX) by visiting AAII Stock Evaluator.

Relative Price Strength of BioCryst Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, BioCryst Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of -1.07%, which translates to a Momentum Score of 49 and is considered to be Average.

Want to learn more about how BioCryst Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BioCryst Pharmaceuticals, Inc. Stock Price: Bottom Line

As of July 31, 2026, BioCryst Pharmaceuticals, Inc.’s stock price is $8.980, which is down 2.81% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BioCryst Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.